Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001.
about
Cytokines as new treatment targets in chronic heart failureClinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology--WARIS II, ESCAMI, PAFAC, RITZ-1 and TIMEA comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumabStatins and dilated cardiomyopathy: do we have enough data?Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH. Impact Of Nicorandil on Angina. Combination Assessment of Ranolazine In Stable Angina. ENhancing Recovery In Coronary Heart Disease patienCarvedilol prevents ovariectomy-induced myocardial contractile dysfunction in female ratHeart failure and the brain: new perspectives.Clinical trials update from the American Heart Association meeting: PROSPER, DIAL, home care monitoring trials, immune modulation therapy, COMPANION and anaemia in heart failure.Assessment of endothelial damage and dysfunction: observations in relation to heart failure.Immunomodulating therapy: new treatment modality in congestive heart failure.The heart failure revascularisation trial (HEART): rationale, design and methodology.Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans.Physiology and pathology of endothelin-1 in renal mesangium.Tezosentan in the treatment of acute heart failure.Biventricular pacing in heart failure: a review.MARCH2 promotes endocytosis and lysosomal sorting of carvedilol-bound β(2)-adrenergic receptorsPathological ventricular remodeling: therapies: part 2 of 2.A regulatory perspective on essential considerations in design and analysis of subgroups when correctly classified.Pathophysiology and potential treatments of pulmonary hypertension due to systolic left heart failure.The duality of chemokines in heart failure.A Review of the Molecular Mechanisms Underlying the Development and Progression of Cardiac Remodeling.Prevention of renal ischemia-reperfusion injury by short hairpin RNA of endothelin A receptor in a rat model.Cholesterol is required for maintaining T-tubule integrity and intercellular connections at intercalated discs in cardiomyocytesManagement of pulmonary hypertension from left heart disease in candidates for orthotopic heart transplantation.Mixed beta3-adrenoceptor agonist and alpha1-adrenoceptor antagonist properties of nebivolol in rat thoracic aorta.Distinctive effects of carvedilol in the non-infarct zone: remodelling of the ligated rat heart linked to oxidative stress.L-Carnitine: a potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure.Effect of nebivolol on left ventricular function in patients with chronic heart failure: a pilot study.Central mineralocorticoid receptor blockade decreases plasma TNF-alpha after coronary artery ligation in rats.Clinical trials update from the European Society of Cardiology Heart Failure meeting: COMET, COMPANION, Tezosentan and SHAPE.Acute myocardial infarction induces hypothalamic cytokine synthesis.Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure.What should be the primary treatment in atrial fibrillation: ventricular rate control or sinus rhythm control with long-term anticoagulation?Overexpression of tumor necrosis factor (TNF)alpha and TNFalpha receptor I in human viral myocarditis: clinicopathologic correlations.In vivo TNF-alpha inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failure.Clinical trials update: highlights of the scientific sessions of The American College of Cardiology 2002: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL.Clinical trials update from the European Society of Cardiology: CARMEN, EARTH, OPTIMAAL, ACE, TEN-HMS, MAGIC, SOLVD-X and PATH-CHF II.
P2860
Q24799394-101A8101-9F0D-482D-8477-9F4AB66DABBAQ28191847-5CE09741-4D65-4F9E-88F6-AC2D1DDA1B96Q28282330-035873AE-680B-4452-83C4-F88F7EE0C6F3Q33787152-0A41AB15-BB52-4B9A-98D0-3C6094FB4C4AQ34506856-FC5F0B92-8CE2-42A9-A8AD-57FC5C952705Q34544785-030D9E66-1DFD-4E81-B7AC-F97E484BB4D5Q35046024-C3FB67E3-2A2C-4F25-8D12-41FE95E8832AQ35057082-959ED5C1-9F48-481C-9BAF-AD4AE9E28731Q35090254-1E114CB4-BB17-4E17-AD5B-85E93C43771CQ35097101-40E6C5EB-DE25-4E7E-8CFF-6A1B2B689D9AQ35150706-2449E8A0-7D27-48D3-9529-E82F083EDB55Q35150715-BBB220D2-F101-4069-A144-3D7E73EDB8BBQ35211305-5C650432-9F92-4FFE-BDB7-0595675D04E9Q35590982-0B428D86-E44A-4D9D-BDD2-A09913B77E36Q36352035-8FDA771D-EECD-4A94-88B7-D9EC21D20450Q36446593-C1180266-3A2B-45D1-8800-26E5D8F544F6Q37312758-F667561F-1FBD-4A55-80D7-D6F940063CA3Q38176063-ECCFD036-4B19-4816-A0A0-9E890B7072D6Q38202309-3D014EAC-9392-4B0A-AC30-836301879F4FQ38375149-ECFB94FA-F9EE-4955-B85F-D9F89F0B4154Q38656290-9A15CF2F-E0BD-461E-BC77-59202E167D33Q39295218-83990FFF-8442-4391-88D7-73AD2659872AQ39714305-7A1CC537-DBA0-47EE-B222-9165CCC630A6Q41302280-0DF2B2F5-1BFD-4F58-874E-3F7C81B86FF3Q42056599-7031FD2A-14BD-438A-80FE-C5DC8555F585Q43237440-D386027D-9DED-4922-AC7C-2CBEF65FF142Q44101881-34F4BA6D-FBF5-45E1-A116-019D341372CBQ44230616-AA78B48B-DE85-496D-85DC-1CA74D2666F2Q44279118-F9C6FC20-F302-414A-B965-987C5A9B0922Q44551641-D0F2ECCD-ABD4-4C14-AD82-C380B34E413AQ44899575-D9E58C7A-9B98-4223-97D3-C9B309DB7615Q45011976-95D182DC-B69C-4A0F-9C35-51C9331FBF12Q46042262-A909A1A2-5ACB-4932-9A6A-4E3EBD04BAD5Q47287920-4A3D8753-A55B-456C-BCC8-39946DBC69FDQ47325021-0859A22B-914E-4B01-858F-285F55454264Q50696171-8386EA28-213D-49B4-B29B-210FD637AB5AQ52954696-62FD14CD-7FCF-4C38-9DE9-90274D51099F
P2860
Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Clinical Trials Update: CAPRIC ...... n College of Cardiology, 2001.
@ast
Clinical Trials Update: CAPRIC ...... n College of Cardiology, 2001.
@en
Clinical Trials Update: CAPRIC ...... n College of Cardiology, 2001.
@nl
type
label
Clinical Trials Update: CAPRIC ...... n College of Cardiology, 2001.
@ast
Clinical Trials Update: CAPRIC ...... n College of Cardiology, 2001.
@en
Clinical Trials Update: CAPRIC ...... n College of Cardiology, 2001.
@nl
prefLabel
Clinical Trials Update: CAPRIC ...... n College of Cardiology, 2001.
@ast
Clinical Trials Update: CAPRIC ...... n College of Cardiology, 2001.
@en
Clinical Trials Update: CAPRIC ...... n College of Cardiology, 2001.
@nl
P2093
P2860
P1476
Clinical Trials Update: CAPRIC ...... an College of Cardiology, 2001
@en
P2093
P2860
P304
P356
10.1016/S1388-9842(01)00149-0
P50
P577
2001-06-01T00:00:00Z